$200K Challenge Sponsor
Areas of Interest
Many of the Challenge Sponsors have specific areas of need, which we've outlined below. Historically, entries that effectively answer these areas of need increase their chances of being chosen as Finalists.
• Particular attention will be given to novel solutions to address unmet needs for women’s health
• Drug delivery and manufacturing technologies that enable multiple new therapeutics and optimizes the patient experience (ex. advanced assembly of multi-specifics)
• Innovative digital and/or automated technologies to support life science operations:
o automation, miniaturization, & high-throughput
o data collection, utilization, & management
• Novel vascular diagnostic and therapeutic medical devices
• Novel endoscopic-related diagnostic and therapeutic medical devices
• AOI #2: Infection Severity and Solving Sepsis - The Solving Sepsis program aims to reduce the incidence, morbidity, mortality, and economic burden of sepsis.
• AOI #5: ReDirect - BARDA is requesting abstract submissions for projects that repurpose existing therapeutics as MCMs against chemical threats (cyanide, opioids, nerve agents, chlorine, sulfur mustard, etc.).
• AOI #8: Bringing Laboratory Testing to the Home - DRIVe is seeking platform technologies for on-demand, at-home detection of biochemical health markers, with a preference for multiplexed biochemical assays.
• AOI #9: Digital Health Tools for Pandemic Preparedness - DRIVe is interested in supporting the development of novel digital health tools that can be the first line of defense and augment existing medical countermeasures in the event of a future infectious disease epidemic or pandemic.
• AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 - DRIVe is seeking abstract submissions for the development of Emergency Use Authorized (EUA), home-based in-vitro diagnostic assays that can detect SARS-CoV-2 in samples collected in a home setting.
• AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection - DRIVe is seeking abstract submissions for (1) technologies that can enable more wide-spread adoption of at-home testing, and (2) improvements on current technological limitations of diagnostic sensitivity/specificity and performance.
• AOI #12: Mitigating Long-term Effects (MILE) of Respiratory Distress - DRIVe is interested in host-targeted therapeutic product candidates as threat agnostic approaches to aid in mitigating long-term outcomes. DRIVe is interested in further study of host therapeutic product candidates that may be implemented early in the progression of acute lung injury to specifically reduce the long-term morbidity and mortality resulting from the initial injury or infectious insult.
• AOI #13: Endotyping for Host-Directed Therapeutics - DRIVe is interested in further de-risking the development of host-directed therapeutics by validating targeted enrollment strategies based on individual patient characteristics, including immune profiling, biomarker analysis, or other methods of patient stratification (i.e, Endotyping for Host-Directed Therapeutics). Ultimately the goal is to increase the likelihood of meeting therapeutic efficacy endpoints by evaluating the drug specifically in the sub-population for which that therapeutic will most benefit.
• Minimally invasive devices or digital health solutions in:
o Peripheral Vascular Interventions
o Urology and Pelvic Health
o Structural Heart spaces
• Cyber physical systems are of particular interest
• Point of care technologies for:
o Sleep disorders
• Devices intended to simplify and improve therapeutic procedures in the women’s health space, filling treatment gaps and advancing patient care. Areas of interest include:
• GYN transvaginal procedures, such as:
o Tubal obstruction (HSG, selective HSG)
o Biopsy collection
o Vaginal Surgery
• GYN Laparoscopic surgery
• Pelvic organ prolapse
• Pelvic/bladder health
• Contraception (non-hormonal)
• OR equipment management
Johnson & Johnson
• 3D Printing
• Digital Surgery
• Sensor technologies
• Vision Care
• AAV and non-viral Gene Therapy
• AAV and non-viral Gene Editing (e.g., CRISPR, epigenetics, other transposase)
• Novel CRISPR-Cas enzymes
• PMO Antisense Oligonucleotides for splice modulation or translational inhibition
• Targeting of Oligonucleotides to muscle tissue
• AAV Engineering and targeting for neurological applications
• Immune modulation for gene therapy/editing
• Promoter engineering for gene therapy/editing
• Non-viral gene therapy/editing delivery to muscle and/or neurological applications